📊 DRMAW Key Takeaways
Is Dermata Therapeutics, Inc. (DRMAW) a Good Investment?
Dermata Therapeutics is a pre-revenue pharmaceutical company with severe financial distress, burning $6.4M in operating cash flow against minimal $161K in revenue. The company is fundamentally unprofitable with negative operating margins exceeding -3600% and deteriorating cash position despite strong liquidity, indicating unsustainable burn rate and high bankruptcy risk without significant capital infusion or commercial success.
Dermata Therapeutics shows very weak fundamentals: despite triple-digit revenue growth, revenue remains immaterial relative to a $5.70M net loss and deeply negative operating and free cash flow. The balance sheet is currently clean and liquid with $4.66M in cash and no long-term debt, but the company’s cash burn, negative returns on assets and equity, and lack of meaningful profitability indicate fragile growth quality and high financing risk.
Why Buy Dermata Therapeutics, Inc. Stock? DRMAW Key Strengths
- Strong liquidity position with 7.66x current ratio and $4.7M cash on hand
- Massive revenue growth of 239% YoY indicating early commercialization attempts
- Minimal debt burden with 0.00x debt-to-equity ratio providing financial flexibility
- Strong near-term liquidity with a 7.66x current ratio and $4.66M cash balance
- No meaningful long-term debt, limiting balance-sheet leverage risk
- Reported revenue growth of 239.4% year over year, indicating some top-line progress
DRMAW Stock Risks: Dermata Therapeutics, Inc. Investment Risks
- Severe operating losses of -$6.4M annually with negative margins exceeding -3600%, indicating non-viable business model
- Cash burn rate of -$6.4M in operating cash flow relative to $4.7M cash reserves implies less than 1 year of runway
- Minimal revenue of $161K insufficient to support R&D and operational costs typical in pharmaceutical industry
- Pharmaceutical sector requires successful clinical trials and FDA approval with no indication of pipeline maturity
- High frequency of insider Form 4 filings (14 in 90 days) may signal uncertainty or liquidity management concerns
- Losses are extreme relative to revenue, with net margin at -3530.5% and operating margin at -3639.9%
- Operating cash flow and free cash flow are both -$6.43M, implying continued cash burn and potential future dilution risk
- Very weak profitability metrics, including ROE of -143.9% and ROA of -112.3%, suggest poor capital efficiency
Key Metrics to Watch
- Operating cash burn rate and months of cash remaining
- Revenue trajectory and path to commercial product profitability
- Clinical trial milestones and regulatory approval progress
- Equity raises and capital adequacy for operations
- Quarterly operating cash burn relative to cash on hand
- Whether revenue growth becomes material enough to narrow operating and net losses
Dermata Therapeutics, Inc. (DRMAW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.66x current ratio provides a solid financial cushion.
DRMAW Profit Margin, ROE & Profitability Analysis
DRMAW vs Healthcare Sector: How Dermata Therapeutics, Inc. Compares
How Dermata Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Dermata Therapeutics, Inc. Stock Overvalued? DRMAW Valuation Analysis 2026
Based on fundamental analysis, Dermata Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Dermata Therapeutics, Inc. Balance Sheet: DRMAW Debt, Cash & Liquidity
DRMAW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Dermata Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-80.32 indicates the company is currently unprofitable.
DRMAW Revenue Growth, EPS Growth & YoY Performance
Dermata Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
DRMAW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Dermata Therapeutics, Inc. (CIK: 0001853816)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DRMAW
What is the AI rating for DRMAW?
Dermata Therapeutics, Inc. (DRMAW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DRMAW's key strengths?
Claude: Strong liquidity position with 7.66x current ratio and $4.7M cash on hand. Massive revenue growth of 239% YoY indicating early commercialization attempts. ChatGPT: Strong near-term liquidity with a 7.66x current ratio and $4.66M cash balance. No meaningful long-term debt, limiting balance-sheet leverage risk.
What are the risks of investing in DRMAW?
Claude: Severe operating losses of -$6.4M annually with negative margins exceeding -3600%, indicating non-viable business model. Cash burn rate of -$6.4M in operating cash flow relative to $4.7M cash reserves implies less than 1 year of runway. ChatGPT: Losses are extreme relative to revenue, with net margin at -3530.5% and operating margin at -3639.9%. Operating cash flow and free cash flow are both -$6.43M, implying continued cash burn and potential future dilution risk.
What is DRMAW's revenue and growth?
Dermata Therapeutics, Inc. reported revenue of $161.4K.
Does DRMAW pay dividends?
Dermata Therapeutics, Inc. does not currently pay dividends.
Where can I find DRMAW SEC filings?
Official SEC filings for Dermata Therapeutics, Inc. (CIK: 0001853816) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DRMAW's EPS?
Dermata Therapeutics, Inc. has a diluted EPS of $-6.64.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DRMAW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Dermata Therapeutics, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DRMAW stock overvalued or undervalued?
Valuation metrics for DRMAW: ROE of -143.9% (sector avg: 15%), net margin of -3,530.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DRMAW stock in 2026?
Our dual AI analysis gives Dermata Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DRMAW's free cash flow?
Dermata Therapeutics, Inc.'s operating cash flow is $-6.4M, with capital expenditures of N/A. FCF margin is -3,983.9%.
How does DRMAW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,530.5% (avg: 12%), ROE -143.9% (avg: 15%), current ratio 7.66 (avg: 2).